A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders

1:1
A new simulation framework leverages pharmacometrics to optimise clinical trial designs for disease-modifying treatments in rare neurological conditions.

The authors present a framework using trial simulations to improve the design of studies targeting rare neurological disorders. By integrating pharmacometric data, the model helps in selecting optimal endpoints and sample sizes to increase the probability of trial success.

Year of publication

2025

Source

CPT: Pharmacometrics & Systems Pharmacology

Author

Ryeznik Y, Hilgers RD, Heussen N, Comets E, Mentré F, Hendrickx N, et al.

You might also be interested in

A new online learning series for ERN professionals, clinicians, researchers, and stakeholders.
The session will introduce the workstream’s activities in data sharing, systematic diagnostic reanalysis, advanced diagnostic pipelines, and genomic and multi-omics innovation.
This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.
For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.